Breaking Finance News

Zacks Investment Research downgraded Accelerate Diagnostics Inc (NASDAQ:AXDX) to Hold in a report released today.

Yesterday Accelerate Diagnostics Inc (NASDAQ:AXDX) traded 2.71% higher at $24.60. The company’s 50-day moving average is $23.99 and its 200-day moving average is $20.70. The last stock close price is up 18.86% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 171,321 shares of the stock were exchanged, down from an average trading volume of 302,458

Zacks Investment Research has downgraded Accelerate Diagnostics Inc (NASDAQ:AXDX) to Hold in a report released on 11/29/2016.

See Chart Below

Accelerate Diagnostics Inc (NASDAQ:AXDX)

Accelerate Diagnostics Inc has a 52 week low of $10.29 and a 52 week high of $28.50 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 2 firms have reported on the stock. The consensus target price is $25.50 with 2 equity analysts rating the company a strong buy, one equity analyst rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and lastly zero equity analysts rating the company a sell.

Brief Synopsis About Accelerate Diagnostics Inc (NASDAQ:AXDX)

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company's technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Company is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The ID/AST System features walk-away automation and consists of a fixed instrument and single-use test kit.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *